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INTRODUCTION: Anatomic imaging alone is often inadequate for tuning systemic treatment for individual tumor
response. Optically based techniques could potentially contribute to fast and objective response monitoring in
personalized cancer therapy. In the present study, we evaluated the feasibility of dual-modality diffuse reflectance
spectroscopy–autofluorescence spectroscopy (DRS-AFS) to monitor the effects of systemic treatment in a mouse
model for hereditary breast cancer. METHODS: Brca1−/−; p53−/− mammary tumors were grown in 36 mice, half
of which were treated with a single dose of cisplatin. Changes in the tumor physiology and morphology were
measured for a period of 1 week using dual-modality DRS-AFS. Liver and muscle tissues were also measured to
distinguish tumor-specific alterations from systemic changes. Model-based analyses were used to derive different
optical parameters like the scattering and absorption coefficients, as well as sources of intrinsic fluorescence.
Histopathologic analysiswasperformed for cross-validationwith trends in optically basedparameters.RESULTS: Treated
tumors showed a significant decrease inMie-scattering slope andMie-to-total scattering fraction and an increase in both
fat volume fraction and tissue oxygenation after 2 days of follow-up. Additionally, significant tumor-specific changes
in the fluorescence spectra were seen. These longitudinal trends were consistent with changes observed in the
histopathologic analysis, such as vital tumor content and formation of fibrosis.CONCLUSIONS: This study demonstrates
that dual-modality DRS-AFS provides quantitative functional information that corresponds well with the degree of
pathologic response. DRS-AFS, in conjunctionwith other imagingmodalities, could be used to optimize systemic cancer
treatment on the basis of early individual tumor response.
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Monitoring of the individual tumor response is crucial for optimizing
systemic treatment in patients with cancer, particularly as treatments
trend toward individualized patient care [1–4]. Therapy response
assessment is generally performed by anatomic imaging using the
standardized Response Evaluation Criteria In Solid Tumors criteria
on the basis of changes in anatomic tumor size [5]. However,
standard-of-care anatomic imaging modalities, such as computed
tomography, are unable to objectively evaluate treatment response at
the early stages of treatment. In addition, shrinkage of tumors can be
minimal even when treatment is effective. This phenomenon is mostobvious in certain tumor types, like sarcomas or gastrointestinal
stromal tumors [6], as well as with new targeted drugs that lack direct
intrinsic cytotoxic activity, such as bevacizumab [7].
A modality that is based on functional contrast rather than on
anatomic features alone may improve response monitoring. An
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using [18F]fluorodeoxyglucose (18F-FDG). Nowadays, 18F-FDG PET
has been used for early-response monitoring and outcome prediction,
although the accuracy is still dependent on the tumor type and the
treatment used [8–10].
In the last decade, optical sensing, by means of diffuse reflectance
spectroscopy (DRS) and autofluorescence spectroscopy (AFS), has
been used to improve the identification of cancerous lesions in various
organs [11–21]. Both modalities enable tissue characterization by
measuring the spectral response after the tissue is illuminated with
a selected spectral band of light. Depending on the tissue composi-
tion and its structure, a specific “optical fingerprint” is acquired. This
optical fingerprint represents specific quantitative morphologic,
biochemical, and functional information from the probed tissue,
making it a promising technique for the detection of chemotherapy-
induced alterations.
Tromberg's group investigated the changes in optically measured
biomarkers during chemotherapy in breast cancer using diffuse
optical spectroscopy (DOS) [22–25]. DOS imaging using a handheld
probe was used to scan the breasts of patients with locally advanced
breast cancer before, during, and after chemotherapy. The results
of these studies showed that optically derived tissue parameters
strongly correlate with and, in some cases, predict pathologic
response. A study by Falou et al. also suggested that responders and
nonresponders could be differentiated with DOS [26]. Finally, the
biomedical engineering group at Duke University (Durham, NC)
showed that a combination of DRS and AFS can be applied to
monitor drug concentrations and tumor physiology in vivo in a
preclinical mouse model [27].
Studies thus far have mainly focused on the noninvasive
application of optical sensing by hand-held optical transducers used
to scan tissue surfaces. This approach has a clear advantage for breast
tumors but may limit the applicability of optical sensing for deep-
seeded tumors such as in the lung or kidney. Recently, we described
an optical needle probe able to perform optical measurements in
tumor tissue [21,28,29]. Optical measurements conducted through
very fine needles (smaller than 27 G) open the potential to assess
treatment response of (solid) tumors at deep-tissue sites [30]. The aim
of this study was to investigate whether dual-modality DRS-AFS,
incorporated in a small needle probe, was able to monitor the
dynamics of tumor response after treatment with cisplatin using a
preclinical mouse model for BRCA1-mutated breast cancer.
Materials and Methods
Animal Study Protocol
In this study, Brca1−/−; p53−/− mammary tumors were generated
in a mouse model for hereditary breast cancer previously described by
Liu et al. [31]. These tumors have been demonstrated to be sensitive
to cisplatin at a maximum tolerated dose (MTD) of 6 mg/kg i.v. [32].
Small fragments of tumor (1-2 mm in diameter) were orthotopi-
cally transplanted into the fourth right mammary fat pad of 36 female
(FVB/N HanHSD WT) animals (The Netherlands Cancer Institute,
Amsterdam, The Netherlands) (6-8 weeks of age) as described
previously [32]. Starting 2 weeks after tumor grafting, the onset of
tumor growth was checked at least three times per week. Tumor size
was determined by caliper measurements (length and width in
millimeters), and tumor volume (in cubic millimeters) was calculated
using the following formula: 0.5 × length × width2.Once the tumor volume reached 400 to 800 mm3, the animals
were separated into control and treatment groups. Animals in the
treatment group (N = 18) received cisplatin (1 mg/ml in saline/
mannitol) at a dose of 6 mg/kg (MTD) in a single i.v. injection into
the tail vein. Animals in the control group (N = 18) received an
equivalent amount of saline.
DRS and AFS tumor measurements were performed in vivo after
inserting the spectroscopy needle percutaneously (through the skin)
into the tumors. Baseline measurements were performed on day 0,
immediately after treatment/placebo administration, and then on
days 1, 2, 4, and 7 afterwards. These time points were selected from
a previous pilot study. To evaluate whether eventual changes in the
optical profile were systemic or tumor specific, eight animals from
each group were randomly chosen for additional in vivo measure-
ments in liver and muscle tissues on days 2, 4, and 7.
After each session of optical measurements, three to five animals
from each group were killed to obtain tumor tissue for histopath-
ologic evaluation. Tumor samples were dissected into three parts:
these were snap frozen in liquid nitrogen, fixed in 4% formalin, or
fixed in acetic acid–formalin ethanol saline.
The tumor model used is known to be very sensitive to the MTD
of cisplatin, whereas nontreated tumors grow rapidly. This could
result in control animals being removed from the experiment on the
basis of humane end points (tumor volume N1500 mm3) or in a
minimal amount of measurable tumor tissue in the treated animals
before the end of the experiment. Therefore, animals with slightly
higher tumor volumes were included in the treatment group.
Throughout the course of the experiment, starting 3 weeks before
the tumor grafting, the animals were given a purified diet to
eliminate autofluorescence from chlorophyll [33]. During the
optical spectroscopy measurements, the animals were deeply
anesthetized using 1.5% isoflurane mixed with oxygen. All animal
procedures were approved by the Animal Ethics Committee of the
Netherlands Cancer Institute.
Optical Spectroscopy Using a Miniaturized Optical Probe
DRS and AFS measurements were performed using a portable
spectroscopic system, which consists of two light sources and two
spectrometers (Figure 1). For the DRS measurements, a Tungsten
halogen broadband light source (360-2500 nm) with an embedded
shutter was used. For AFS, the system was equipped with a
semiconductor laser (λ = 377 nm) to induce autofluorescence. One
spectrometer was used to resolve light in the visible wavelength
range, i.e., 400 until 1100 nm (DU420A-BRDD; Andor Tech-
nology, Belfast, Northern Ireland), the other to resolve near-infrared
light from 900 to 1700 nm (DU492A-1.7; Andor Technology).
The spectrometers were controlled by a custom-made LabVIEW
software user interface (National Instruments, Austin, TX) to acquire
and save the data. The calibration procedure has been described
elaborately by Nachabe et al. [34].
A custom fiber-optic needle that can probe tissue at the needle tip
was developed. The needle consisted of a 21-G (0.82 mm) outer
cannula and a 22-G adjustable stylet (Figure 1B), containing four
identical fibers with a core diameter of 100 μm. To minimize tissue
damage, the optical fibers were retracted during needle insertion.
The optical fibers were protruded after positioning the needle at the
right position to establish optimal tissue contact. Two fibers were
connected to the broadband light source and laser, whereas the two
other fibers were connected to the spectrometers to capture diffusely
Figure 1. Schematic overview of the combined DRS and AFS optical setup. The system measures diffuse reflectance (400-1600 nm)
and intrinsic fluorescence (400-800 nm) of tissue through the use of a miniaturized 21-G needle with a retractable inner fiber-
optic stylet.
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source-detector separations (SDSs) were used (1.5 and 0.15 mm).
The spectra acquired with the 1.5-mm SDS were used for the DRS
data analyses, whereas the DRS spectra measured with the 0.15-mm
SDS were used to correct for absorption and scattering in the
fluorescence spectra.
Diffuse Reflectance Spectral Analysis
Three to five DRS spectra were collected from each animal on each
measurement day, consecutively. To interpret the acquired DRS
spectra, a widely accepted analytical model, introduced by Farrell
et al. [35], was used to estimate the various DRS absorption and
scattering coefficients. The absorption coefficients represent the
concentration of physiologically relevant absorbers in the tissue, such
as hemoglobin, water, and fat, as well as functional parameters like
tissue oxygenation. The main scattering parameters are the reduced
scattering coefficient (at 800 nm), the reduced scattering slope of the
Mie scatterer (Mie-scattering slope), and the Mie-to-total scattering
fraction. The Mie-scattering slope is related to the average particle size
[36]. In the Mie-to-total scattering fraction, the total scattering of
tissue is assumed to be composed of Mie and Rayleigh scattering. In
tissue, Mie scattering represents scattering caused by biologic cells and
cellular components, whereas Rayleigh scattering is elastic scattering
of light by particles that are much smaller than the wavelength of light
(e.g., macromolecular aggregates such as collagen fibrils). The vali-
dation of the DRS analytic method has been described previously by
our group [34,37].
Intrinsic Fluorescence Modeling and Quantification
Intrinsic fluorescence from the tissue was calculated by correcting
the acquired fluorescence spectra for absorption and scattering using
the short SDS DRS spectra. For the latter, a modified photon
migration method [38] was used on the basis of the work by Müller et
al. [39] and Zhang et al. [40]. The corrected spectra were fitted using
the fluorescence spectra (excitation at 377 nm) of endogenous tissue
fluorophores [collagen, elastin, nicotinamide adenine dinucleotide
(NADH), and flavin adenine dinucleotid (FAD)] as a priori knowl-edge. The optical oxidation-reduction (redox) ratio, which is linked
to the metabolic state of the tissue, was defined as NADH/(NADH
+FAD) [41,42]. Because collagen and elastin have almost identical
fluorescence spectra, estimated amounts of collagen and elastin were
combined as collagen + elastin.
In case the tissue contained diagnostic levels of endogenous fluo-
rophores other than the ones included in the standard fit model, the
area underneath the fitted curve (known fluorophores) was subtracted
from the total area under the original curve (measured fluorescence).
Histopathologic Analyses
Samples were stained with both standard hematoxylin and eosin
(Merck, Darmstadt, Germany) (HE) and Masson trichrome (MT)
(Sigma-Aldrich, St. Louis, MO) dyes. The HE-stained sections were
used to quantify vital, necrotic, and fibrotic tissue fractions. The
necrotic and fibrotic fractions were calculated as a percentage of
the overall tissue area across each section. For this purpose, at least 10
different fields were investigated at a 400× magnification.
Immunohistochemical analysis of tumors was performed using
anti-γH2AX [rabbit polyclonal; Cell Signaling Technology (Beverly,
MA), No. 2577, 1:50 in 1% BSA diluted in phosphate saline buffer],
anti–cleaved caspase 3 (CC3) [rabbit polyclonal; Cell Signaling
Technology, No. 9661, 1:100 in 1% phosphate-buffered saline with
bovine serum albumin], and anti–Ki-67 probes (Dako (Glostrup,
Denmark); 1:100). For evaluation of the amount of lipids, frozen
sections were mounted on glass slides and stained with Oil Red O
(Sigma-Aldrich, St. Louis, MO). All histopathology was evaluated by
an experienced pathologist in a blinded study setting. The pathology
findings were used to cross-validate the longitudinal changes in the
optical end-points.
Two-Photon Excitation Microscopy
Intrinsic fluorescence in tumor was imaged using a two-photon
confocal microscopy setup. These experiments were carried out to
relate the differences in fluorescence spectra obtained with AFS to
specific structures in the tissue slices. Snap-frozen tumor pieces were
sliced in thick sections (25 μm), kept unstained and unfixed, and
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source was a Ti:Sapphire laser (Tsunami, Spectra Physics, Santa
Clara, CA) tuned to 790 nm. The excitation light (equivalent to a
single-photon excitation wavelength of 395 nm) was delivered to, and
the emitted light was collected from the sample through a Leica
Confocal microscope [with a Leica (Mannheim, Germany) HCX
IRAPO 25× water immersion objective with an NA of 0.95] coupled
to a Leica TCS SP5 tandem scan head operating at 500 lines per
second. A photomultiplier served as the detector. For each tumor
sample, fluorescence images were obtained in the wavelength ranges
of 400 to 500 nm, 500 to 600 nm, and 600 to 700 nm. This was
done to compare the relative intensity of fluorescence at these spectral
ranges between treated and control animals.
Statistical Analysis
To examine the trends in optical parameters over time, a linear
regression model was performed in MATLAB 7.13 (MathWorks Inc,
Natick, MA). The fixed-effects terms in the models were treatment
(controls vs cisplatin), time (day), and their interactions. A slope and
intercept were fit for the data of both the treated and control groups
using maximum likelihood estimation. For the significance of fixed
effects, a likelihood ratio test was statistically compared to a χ2
distribution with 1 df (for one coefficient being eliminated). For all
tests, statistical significance was set at P b .05.
Results
Longitudinal Trends in DRS Parameters and
Tumor Volume
DRS parameter quantification was performed as part of the model-
based data analysis using a total of 712 DRS spectra. The longitudinal
changes for the average tumor volume and various DRS parameters
over time are shown in Figure 2. In the control animals, the tumor
volume increased during the entire follow-up period, whereas the
tumors of the cisplatin-treated animals started to shrink 2 days afterFigure 2. Longitudinal changes in tumor volume and DRS paramete
scattering slope (B), Mie-to-total scattering fraction (C), total hemogl
fraction (G), and water volume fraction (H). The bars represent the m
each particular time point, for both the treated (red) and control (blue
lines. P values are shown at the top of each plot.treatment. For the DRS parameters, the trends during follow-up were
significantly different between the treated and the control groups for
the Mie-scattering slope (P b .0001), Mie-to-total scattering fraction
(P b .001), tissue oxygenation (P = .035), and fat volume fraction
(P b .0001).
Longitudinal Trends in AFS Parameters
The fluorescence spectra and corresponding model fits for two
representative animals (one treated and one control animal) on days
0, 2, 4, and 7 are shown in Figure 3. In the tumor of the treated
animal, an increasing deviation between the measurements and the
fitted curves was observed from day 2 onwards, between 500 and
800 nm. This indicates that fluorophores other than the ones
included in the standard fit model (collagen, elastin, NADH, and
FAD) were measured. This additional fluorescence activity (from
now on called fluorescence residual) was seen in all the treated
tumors at days 4 and 7.
The longitudinal kinetics for each model-fitted AFS parameter and
the calculated fluorescence residual across all treated and control
animals are shown in Figure 4. The plotted linear trend for the
fluorescence residual in tumor was significantly different between the
treated and the control groups (P = .018). No significant trends were
observed for the total fluorescence intensity, collagen + elastin, and
the optical redox ratio.
Figure 5 shows the longitudinal changes of the fluorescence
residual in tumor, liver, and muscle across all animals from both
groups. The additional fluorescence is not present in muscle and liver
tissues, indicating a tumor-specific effect.
Two-Photon Confocal Microscopy
In an attempt to better understand the origin of the additional
autofluorescent emission (mainly above 600 nm) seen in the treated
animals, two-photon confocal fluorescence microscopy images
recorded in a spectral range of 600 to 700 nm were compared with
adjacent tissue sections that were stained with HE (Figure 6). Thers measured for both groups across time: tumor volume (A), Mie-
obin (D), tissue oxygenation (E), reduced scattering (F), fat volume
eans for each parameter computed across all available animals, at
) groups. The dashed lines represent the corresponding regression
Figure 3. Autofluorescence spectra for a representative animal in the control group and the treated group during 1 week of follow-up.
The blue lines are the fluorescence measurements, whereas the red lines are the results of the model-based fitting procedure. The
green lines illustrate the residual due to the presence of additional fluorescence, which is specifically seen in the treated animals after
2 days.
234 Treatment Response Monitoring by Optical Spectroscopy Spliethoff et al. Translational Oncology Vol. 7, No. 2, 2014samples were collected after 1 week of follow-up, i.e., when the
differences seen in AFS signals were maximal. In the treated tumor
samples, numerous fluorescent foci were present. These foci corre-
lated with cellular structures rather than with collagen deposits or
necrotic areas. It remains to be determined whether this specific
fluorescence originated from stromal or tumor cells. For the two-
photon images recorded in the spectral ranges 400 to 500 nm and
500 to 600 nm, no considerable differences were seen when comparing
both groups.
Evaluation of Histology and Histochemical Biomarkers
The evaluation of pathologic response of tumors to cisplatin using
various histologic dyes and immunohistochemical biomarkers is
illustrated in Figure 7. A strong increase in nuclear DNA damage was
seen 24 hours after cisplatin administration using γ-H2AX as a marker.
From day 2 onwards, a significant decrease in the proliferation marker
Ki-67 and an increase in apoptosis-related cell death (CC3marker) wereFigure 4. Longitudinal trends in AFS parametersmeasured for both gro
(B), optical redox ratio (C), and fluorescence residual (D). The bars rep
animals, at each particular time point, for both the treated (red) an
represent the corresponding regression lines. P values are shown atobserved. Analysis of MT-stained slides showed increased amounts of
fibrotic tissue 4 to 7 days after treatment that corresponded to the HE
images. An increase in lipids (Oil Red O) was seen over time.
In Figure 8, A and B, fractions of vital, necrotic, and fibrotic tumor
tissues for both groups are shown as quantified on theHE-stained tissue
slides. These data indicate that the pathologic response to cisplatin in
this tumor model corresponds with the replacement of viable tumor
tissue by fibrosis, without a considerable increase in necrosis. The
longitudinal changes in these histopathologic end points were compared
against changes in prominent optical parameters as shown in Figure 8,
C and D. In the treated group, a major shift in both histology and
optical end points was seen, whereas minimal changes were observed
across all of these parameters in the control group.
Discussion
In this study, a combination of DRS and AFS was used to investigate
cisplatin-induced changes in tumor physiology and morphologyups across time: total fluorescence intensity (A), collagen + elastin
resent the means for each parameter computed across all available
d control (blue) groups. The error bars are SEs. The dashed lines
the top of each.
Figure 5. Course of fluorescence residual in tumor (A), liver tissue (B), andmuscle tissue (C) over time. The data of muscle and liver tissues
shown here were obtained from 16 (8 per group) of the animals that were killed at day 2, 4, or 7, whereas A represents the full cohort. The
error bars are SEs.
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cancer. The changes in optical end points were compared against the
degree of pathologic response. The results showed that various DRS
and AFS parameters in the treated animals significantly changed
throughout the course of treatment relative to the untreated animals.
These parameters were the Mie-scattering slope (P b .0001), Mie-to-
total scattering fraction (P b .001), tissue oxygenation (P = .035), fat
volume fraction (P b .0001), and fluorescence residual (P b .018).Figure 6. Two-photon confocal microscopy images (600-700 nm) of tu
Effective excitation was at 395 nm, and the intensity scale is the sam
after 1 week of follow-up, i.e., when the differences seen in AFS
fluorescent foci were present within the cells. B and D show correspFurthermore, the observed changes appeared to be proportional to the
degree of vital tumor tissue and the formation of fibrosis.
Optical scattering characteristics are dependent on the size and
density of cell nuclei and organelles as well as on the composition of the
extracellular matrix (e.g., macromolecular aggregates and collagen
fibers). In the histopathologic evaluation, considerable alterations in the
extracellularmatrix (formation of fibrosis) and in the size and the density
of (sub) cellular structures were observed in the tumors of the treatedmor sections of a representative control (A) and treated animal (C).
e in both of the two-photon images. The samples were collected
signals were maximal. In the treated tumor samples, numerous
onding HE images.
Figure 7. Tumor pathologic response to an MTD cisplatin. Scale bar, 100 μm. HE- (A) and MT- (B) stained tumor sections show
replacement of viable tumor tissue by fibrosis, especially after day 2 onwards. The γ-H2AX (C), Ki-67 (D), and anti-CC3 (E) markers
showed a strong increase in DNA damage, a decrease in proliferation, and an increase in apoptosis-related cell death, respectively. An
increase in the amount of lipids (Oil Red O stain) was seen across time.
236 Treatment Response Monitoring by Optical Spectroscopy Spliethoff et al. Translational Oncology Vol. 7, No. 2, 2014animals. These morphologic and structural changesmay lead to changes
in tissue-scattering properties that in turn may translate into changes in
the Mie-scattering slope and Mie-to-total scattering fraction. Although
significant fibrosis and cellular disintegration after treatment with
cisplatinmay explain these specific changes, further research is needed to
provide a better understanding of these relationships.
Tumor tissue oxygenation values of untreated animals remained
hypoxic over time, whereas tumors of treated animals became pro-
gressively more oxygenated. This is consistent with previously re-
ported results where improved oxygenation of tumor tissue was
observed due to tumor regression and altered metabolism after
treatment with doxorubicin [27,43,44]. For example, Vishwanath
et al. performed DRS using a surface probe and showed that
mammary-tumor tissue oxygenation in treated mice increased after
doxorubicin administration relative to the untreated controls.
A particularly interesting finding was the additional fluorescence
observed in the treated group. On the basis of two-photon imaging,
the extra fluorescence was specifically found in the cellular com-
ponents of tumor tissue treated with cisplatin. Fluorescence was
tumor specific and not observed in liver or muscle tissue of the treated
animals. Earlier research has shown that some cancers accumulate
diagnostic levels of endogenous protoporphyrin IX and other meta-bolic products of porphyrin as a result of tumor-specific metabolic
alterations [45,46]. Quantification of porphyrins using standard fit
procedures is challenging, because the exact wavelength of the fluo-
rescence bands of porphyrins strongly depend on the environment
(e.g., pH) where it is measured [45,46]. Whether porphyrin
fluorescence is primarily associated with certain tumor types or
with response to systemic therapy is unknown. The exact basis of the
additional autofluorescence emission observed in this study will be
investigated in future studies.
The AFS spectra were fitted using the intrinsic fluorescence
spectra of collagen, elastin, NADH, and FAD as a priori knowledge.
No considerable change over time was observed in these parameters.
This may be due to the presence of significant amounts of unknown
fluorescence that was not taken into account in the AFS curve
fitting procedure and hence may have influenced quantification of
minor effects of the other fluorophores such as collagen, elastin,
NADH, and FAD.
The use of a broad spectral range in combination with a model-
based analysis allows proper estimation of most individual DRS
parameters. Some caution is advised concerning the total hemoglobin
contents within this study. Although a thin 21-G optical needle
(0.72mm) was used, minor bleeding at the tip of the needle may have
Figure 8. Comparison of histology and optical spectroscopy end points. The upper two figures show the temporal changes in mean
fractions of vital tumor tissue, necrosis, and fibrosis for the control (A) and treated (B) groups, as assessed by histologic staining using HE.
The lower two figures (C and D) show temporal changes in the Mie-scattering slope, the Mie-to-total scattering fraction, and the
fluorescence residual for both groups. Error bars indicate SE.
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in a previous clinical study by Brown et al. [47] a 14-G coaxial
cannula combined with a fiber-optic needle was successfully used to
measure tissue optical properties in human breast tissue during
surgery. This indicates that small bleedings are not necessarily a
problem when optical spectroscopy technology is applied in vivo. It
also indicates the feasibility, within a clinical setting, of monitoring
changes in perfusion and blood content of tumors by using a needle-
based fiber-optic tool. Both parameters may be of specific interest for
evaluation of tumor responses to antiangiogenic drugs.
Earlier research suggests that cancer cells show specific alterations
in different aspects of lipid metabolism. For example, the high
proliferation of cancer cells requires large amounts of lipids as build-
ing blocks for biologic membranes [48], whereas apoptosis-related
cell death is associated with an accumulation of cellular lipids [49].
Our setup is able to measure in the infrared wavelength range up to
1600 nm where fat and water absorption bands exist. This enables
reliable estimation of these substances [34]. In this study, histopath-
ologic analysis using Oil Red O showed an increase in the amount of
lipids in tumor sections for the treated animals. This is consistent with
the increase in apoptosis-related cell death seen in the anti-CC3 images
and the clear increase in fat volume fraction (P b .0001) measured with
DRS for the same animals. Regarding the control group, the high offset
of fat percentage at day 0 and the decrease in the average fat volume
fraction during follow-up may be explained by the lower average
“starting” tumor volume in the control animals (compared to the treated
animals), as well as the subsequent progressive growth of these tumors
and the associated decrease in lipid content.
In the current study, we used a tumor model that is known to be
very sensitive to the MTD of cisplatin. Further studies in animalmodels with drug-resistant tumors are needed to explore the differ-
ences in optical parameters in these settings. Moreover, it is likely
that the changes in tumor tissue vary on the basis of the specific
treatment given. To provide a more complete understanding of the
relationship between optical spectroscopy parameters and pathologic
response, the effect of other drugs on spectroscopy parameters needs
to be investigated further.
Conventional anatomic imaging alone lacks the sensitivity for
early-response monitoring or assessing the effect of new targeted
therapies that do not necessarily result in a change in tumor size. For
these purposes, functional information, such as that obtained by 18F-
FDG PET [7–9] and contrast-enhanced magnetic resonance imaging
[50] is more suitable. Optical spectroscopy is a relatively new
functional imaging technique that may contribute to fast-response
evaluation and timely shifting of systemic treatment. This could be of
great clinical benefit, even when it requires (minimal) invasive optical
spectroscopy measurements in the tumor. In a time of personalized
medicine, repeated tumor core biopsy is increasingly used during the
course of treatment to generate a genetic or epigenetic profile allowing
selection of the best possible treatment. Repeated biopsies may,
however, be confounded by intratumor heterogeneity [51]. By
performing optical spectroscopy along the needle path, an “optical
tumor profile” can be recorded covering a relatively large volume of
tumor tissue. For example, Nachabe et al. [52] showed that optical
spectroscopy measurements at the tip of a needle allowed real-time
tissue characterization during percutaneous interventions. As such,
optical spectroscopy offers the potential to measure real time
alterations in the optical profile during systemic treatment. In this
way, it may help to personalize cancer treatments and may improve
cost effectiveness of systemic treatment in cancer.
238 Treatment Response Monitoring by Optical Spectroscopy Spliethoff et al. Translational Oncology Vol. 7, No. 2, 2014Conclusions
In summary, this study shows that dual-modality DRS–AFS provides
quantitative functional information that corresponds well with the
degree of pathologic response of systemic treatment. This could be
of considerable value for the monitoring and prediction of cancer
therapy efficacy on the basis of individual patient response. Further
studies including resistant tumor models and various therapeutic
drugs are needed to verify the initial findings of this work.
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